Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology (OLMA) will participate in four upcoming investor conferences, with fireside chats scheduled from November 10 through November 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology (OLMA) will participate in four upcoming investor conferences, with fireside chats scheduled from November 10 through November 18, 2026.
The events are Guggenheim in Boston on November 10, Stifel in New York on November 11, UBS in London on November 17, and Jefferies in London on November 18. Live webcasts and recordings will be available on Olema’s investor relations website, as permitted by each event host.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
Guggenheim 3rd Annual Healthcare Innovation Conference
Date and Time: November 10, 2026 at 10 a.m. ET
Format: Fireside Chat
Location: Boston, MA
Stifel 2026 Healthcare Conference
Date and Time: November 11, 2026 at 10:40 a.m. ET
Format: Fireside Chat
Location: New York, NY
UBS Global Biopharma Conference
Date and Time: November 17, 2026 at 3:20 p.m. GMT/10:20 a.m. ET
Format: Fireside Chat
Location: London, England
Jefferies Global Healthcare Conference
Date and Time: November 18, 2026 at 4 p.m. GMT/11 a.m. ET
Format: Fireside Chat
Location: London, England
Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
